Methylation of SPARCL1 Is Associated with Oncologic Outcome of Advanced Upper Urinary Tract Urothelial Carcinoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Apr 17

PMID 30987093

Citations 7

Authors

Hao-Lun Luo

Po-Huang Chiang

Chun-Chieh Huang

Yu-Li Su

Min-Tse Sung

Eing-Mei Tsai

Chang-Shen Lin

Po-Hui Chiang

Affiliations

Soon will be listed here.

Abstract

Advanced upper urinary tract urothelial carcinoma (UTUC) is often associated with poor oncologic outcomes. The secreted protein acidic and rich in cysteine-like 1 (SPARCL1) protein, belongs to the SPARC-related family of matricellular proteins. Much literature has been published describing the role of SPARCL1 in the prognosis many cancers. In this study, methylated promoter regions in high-grade and high-stage upper urinary urothelial tumours compared with normal urothelium were analyzed and revealed that was the most significantly hypermethylated gene in UTUC tissues. Then we prospectively collected UTUC samples and adjacent normal urothelium for pyrosequencing validation, identifying significant CpG site methylation in UTUC tissues. In addition, SPARCL1 RNA levels were significantly lower in UTUC samples. Multivariate Cox regression analysis from 78 patients with solitary renal pelvic or ureteral pT3N0M0 urothelial carcinomas revealed that only negative SPARCL1 expression and nonpapillary tumour architecture were independently associated with systemic recurrence ( = 0.011 and 0.008, respectively). In vitro studies revealed that the behaviour of BFTC-909 cells was less aggressive and more sensitive to radiation or chemotherapy after SPARCL1 overexpression. Thus, SPARCL1 could be considered as a prognostic marker and help decision-making in clinical practice.

Citing Articles

Genetic Interference of FGFR3 Impedes Invasion of Upper Tract Urothelial Carcinoma Cells by Alleviating RAS/MAPK Signal Activity.

Huang G, Huang C, Kang C, Cheng Y, Tsai P, Kao Y Int J Mol Sci. 2023; 24(2).

PMID: 36675289 PMC: 9863353. DOI: 10.3390/ijms24021776.

MiR-26a-5p as a useful therapeutic target for upper tract urothelial carcinoma by regulating WNT5A/β-catenin signaling.

Chung Y, Cheng Y, Kao Y, Tsai W, Huang G, Chen Y Sci Rep. 2022; 12(1):6955.

PMID: 35484165 PMC: 9050734. DOI: 10.1038/s41598-022-08091-6.

DNA Hypomethylation Is Associated with the Overexpression of INHBA in Upper Tract Urothelial Carcinoma.

Kao C, Chang Y, Liu H, Wu S, Meng E, Cha T Int J Mol Sci. 2022; 23(4).

PMID: 35216189 PMC: 8877459. DOI: 10.3390/ijms23042072.

Extracorporeal Shock Wave Enhances the Cisplatin Efficacy by Improving Tissue Infiltration and Cellular Uptake in an Upper Urinary Tract Cancer Animal and Human-Derived Organoid Model.

Luo H, Liu H, Chang Y, Su Y, Huang C, Lin X Cancers (Basel). 2021; 13(18).

PMID: 34572785 PMC: 8471724. DOI: 10.3390/cancers13184558.

Hypomethylated RRBP1 Potentiates Tumor Malignancy and Chemoresistance in Upper Tract Urothelial Carcinoma.

Luo H, Liu H, Chang Y, Sung M, Chen P, Su Y Int J Mol Sci. 2021; 22(16).

PMID: 34445467 PMC: 8395942. DOI: 10.3390/ijms22168761.

References

Chou Y, Huang C . Unusual clinical presentation of upper urothelial carcinoma in Taiwan. Cancer. 1999; 85(6):1342-4. View

Claeskens A, Ongenae N, Neefs J, Cheyns P, Kaijen P, Cools M . Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer. 2000; 82(6):1123-30. PMC: 2363342. DOI: 10.1054/bjoc.1999.1051. View

Esposito I, Kayed H, Keleg S, Giese T, Sage E, Schirmacher P . Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia. 2007; 9(1):8-17. PMC: 1803032. DOI: 10.1593/neo.06646. View

Kaag M, OMalley R, OMalley P, Godoy G, Chen M, Smaldone M . Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol. 2010; 58(4):581-7. PMC: 3677959. DOI: 10.1016/j.eururo.2010.06.029. View

Li P, Qian J, Yu G, Chen Y, Liu K, Li J . Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol. 2011; 105(1):31-7. DOI: 10.1002/jso.22025. View

Kim K, You D, Jeong I, Hong J, Ahn H, Kim C . Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol. 2012; 31(8):1643-9. DOI: 10.1016/j.urolonc.2012.04.014. View

Hu H, Zhang H, Ge W, Liu X, Loera S, Chu P . Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res. 2012; 18(19):5438-48. DOI: 10.1158/1078-0432.CCR-12-0124. View

Hurley P, Marchionni L, Simons B, Ross A, Peskoe S, Miller R . Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci U S A. 2012; 109(37):14977-82. PMC: 3443123. DOI: 10.1073/pnas.1203525109. View

Yin F, Liu X, Li D, Wang Q, Zhang W, Li L . Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer. Int J Oncol. 2013; 42(4):1305-16. DOI: 10.3892/ijo.2013.1819. View

10.

Luo H, Kang C, Chen Y, Chuang Y, Lee W, Cheng Y . Diagnostic ureteroscopy independently correlates with intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Ann Surg Oncol. 2013; 20(9):3121-6. DOI: 10.1245/s10434-013-3000-z. View

11.

Leow J, Martin-Doyle W, Fay A, Choueiri T, Chang S, Bellmunt J . A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol. 2014; 66(3):529-41. DOI: 10.1016/j.eururo.2014.03.003. View

12.

Hamidi T, Singh A, Chen T . Genetic alterations of DNA methylation machinery in human diseases. Epigenomics. 2015; 7(2):247-65. DOI: 10.2217/epi.14.80. View

13.

Luo H, Sung M, Tsai E, Lin C, Lee N, Chung Y . Expression of Estrogen Receptor Beta Predicts Oncologic Outcome of pT3 Upper Urinary Tract Urothelial Carcinoma Better Than Aggressive Pathological Features. Sci Rep. 2016; 6:24263. PMC: 4823660. DOI: 10.1038/srep24263. View

14.

Schulz W, Goering W . DNA methylation in urothelial carcinoma. Epigenomics. 2016; 8(10):1415-1428. DOI: 10.2217/epi-2016-0064. View

15.

Krabbe L, Eminaga O, Shariat S, Hutchinson R, Lotan Y, Sagalowsky A . Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2016; 197(3 Pt 1):580-589. DOI: 10.1016/j.juro.2016.09.078. View

16.

Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L . Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017; 376(11):1015-1026. PMC: 5635424. DOI: 10.1056/NEJMoa1613683. View

17.

Zhao S, Jiang Y, Xu N, Li Q, Zhang Q, Wang S . SPARCL1 suppresses osteosarcoma metastasis and recruits macrophages by activation of canonical WNT/β-catenin signaling through stabilization of the WNT-receptor complex. Oncogene. 2017; 37(8):1049-1061. PMC: 5851113. DOI: 10.1038/onc.2017.403. View

18.

Hu H, Cai W, Zheng S, Ge W . SPARCL1, a Novel Prognostic Predictive Factor for GI Malignancies: a Meta-Analysis. Cell Physiol Biochem. 2017; 44(4):1485-1496. DOI: 10.1159/000485584. View

19.

Ma Y, Xu Y, Li L . SPARCL1 suppresses the proliferation and migration of human ovarian cancer cells via the MEK/ERK signaling. Exp Ther Med. 2018; 16(4):3195-3201. PMC: 6143840. DOI: 10.3892/etm.2018.6575. View

20.

Girard J, Springer T . Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity. 1995; 2(1):113-23. DOI: 10.1016/1074-7613(95)90083-7. View